This trial is active, not recruiting.

Conditions basal cell carcinoma of the skin, recurrent skin cancer
Treatments vismodegib, mohs surgery
Target PTCH1
Sponsor Stanford University
Collaborator National Cancer Institute (NCI)
Start date June 2012
End date November 2017
Trial size 20 participants
Trial identifier NCT01631331, 24313, NCI-2012-01055, SKIN0012


The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Patients receive vismodegib PO daily for 3-6 months based on the size of basal cell carcinoma and then undergo Mohs surgery.
vismodegib Erivedge
Given PO
mohs surgery
Undergo Mohs surgery

Primary Outcomes

Anti-tumor effect as measured by the percent change in surgical defect area against the null hypothesis of no change after the treatment period using calipers and photographs
time frame: Baseline to 6 months

Secondary Outcomes

Proportion of tumors with skip lesions present determined using bread-loafing of tumor block and histology
time frame: Assessed up to 6 months
Average area of the subclinical tumor invasion calculated from the pre-surgical skin markings and by comparing the initial clinical margins to the final Mohs defect
time frame: Assessed up to 6 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Study patients must have at least one BCC, > 5 mm, eligible for Mohs surgical removal; patients with BCCs that have been treated before (recurrent BCCs, BCCs that failed other chemotherapy) are eligible for this trial, if they meet size criteria - No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status will be employed - Normal hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x the upper limit of normal (ULN) - Normal renal function : normal serum creatinine defined as <= 2.5 mg/dL - Clinically acceptable complete blood count (CBC) - Ability to understand and the willingness to sign a written informed consent document - The patient is willing to forego surgical treatment of BCCs by up to 6 months, except when the principal investigator (PI) believes that delay in treatment potentially might compromise the health of the subject - Documented negative serum pregnancy test for women of childbearing potential, with agreement to the use of two acceptable methods of contraception during the study and for 7 months after discontinuation of vismodegib - For men with female partners of childbearing potential, agreement to use a latex, non-latex, or any other male condom and to advise their female partners to use an additional acceptable method of birth control during the study and for 2 months after discontinuation of study drug - Be willing to not donate blood or semen for three months following discontinuation of study medications Exclusion Criteria: - The patient has a history of invasive cancer within the past five years excluding non-melanoma skin cancer, stage I cervical cancer, ductal carcinoma in situ of the breast, or chronic lymphocytic leukemia (CLL) stage 0 - The subject has uncontrolled systemic disease, including known human immunodeficiency virus (HIV) positive patients: - The patient has history of congestive heart failure - The patient has clinically important history of liver disease, including viral or hepatitis, current alcohol abuse, or cirrhosis - The patient has any condition or situation which in the investigator's opinion may put the patient at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study; this includes history of other skin conditions or disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk from treatment complications - The patient has a history of hypersensitivity to any of the ingredients in the study medication formulations - The patient is willing to abstain from application of non-study topical medications to the skin for the duration of the study, including prescription and over the counter preparations; for example, topical preparations containing corticosteroids or vitamin A derivatives are not allowed - Pregnant or nursing patients will be excluded from the study

Additional Information

Official title A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCC)
Principal investigator Jean Tang
Description PRIMARY OBJECTIVES: I. The percent reduction in surgical defect area/size surrounding BCC tumor pre and post-vismodegib. SECONDARY OBJECTIVES: I. Bread-loafing histology will be used to determine if the tumor after vismodegib shrinks as one discrete lesion (contiguous) vs. with skip areas (non-contiguous) II. The percent reduction in tumor size pre and post-vismodegib. III. Safety, tolerability and percent drop-out after 3 vs. 6 months of vismodegib in otherwise healthy patients. OUTLINE: Patients receive vismodegib orally (PO) once daily (QD) for up to 3 months if the initial BCC size is < 2 cm and superficial or for up to 6 months if the initial BCC size is >= 2 cm or non-superficial. After completion of vismodegib treatment, patients undergo Mohs surgery. After completion of study treatment, patients are followed up for 6 months.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Stanford University.